Health care expenditures in the United States soared to nearly $6 trillion in 2025, according to recent data released by CMS actuaries. Spending hit $5.7 trillion, marking the third consecutive year in which growth exceeded 7%. The sharp increase is attributed in part to the rising costs of pricey medications, particularly GLP-1s, which are used to treat obesity.
The data underscores a persistent trend of escalating health care costs that poses significant challenges for insurers, employers, and consumers alike. For health insurance providers such as Astiva Health, these rising expenses are a major concern as they navigate premium pricing and coverage decisions.
GLP-1 receptor agonists, originally developed for diabetes management, have gained widespread use for weight loss, driving up overall drug spending. The high demand for these medications has strained health care budgets and raised questions about long-term affordability.
The implications of this spending surge are far-reaching. Employers may face higher premiums for group health plans, potentially leading to reduced coverage or increased cost-sharing for employees. Individuals with health insurance could see higher deductibles and copays, while the uninsured may find care even less accessible.
For the health care industry, the continued growth in spending signals a need for cost-containment strategies. Payers and providers are under pressure to manage drug costs, perhaps through formulary restrictions or negotiating lower prices with manufacturers. However, the introduction of new, expensive therapies is likely to keep upward pressure on spending.
Policy makers are also affected, as rising health care costs consume a larger share of the federal budget. Medicare and Medicaid expenditures are expected to increase, prompting debates about reforms to control spending without compromising care quality.
The CMS data serves as a stark reminder of the financial burden of health care in the U.S. With spending on track to exceed $6 trillion in the near future, stakeholders across the spectrum must grapple with the reality of unsustainable cost growth.
